Type 2 diabetes mellitus
Conditions
Interventions
Sponsors
Abe Diabetes Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.HbA1c>=7.0% 2.Patients who have received treatment of type 2 diabetes mellitus(diet therapy, exercise therapy and so on) 3.eGFR>=100 ml/min/1.73m2 4.Patients who have received DPP4 inhibitor dose of them are stable over 8 weeks. 5.Age >= 20 years and Male and Female 6.Outpatients 7.Consent to study participation has been obtained in writing from the patient personally
Exclusion criteria
Exclusion criteria: 1. The amount of change of eGFR between screening and initiation of study is more than 10ml/min/1.73m2 2. Patient with type 1 diabetes mellitus or with history of secondary diabetes mellitus 3. Patients with history of or concurrent complication that affect renal function(renal disease, nephrotic syndrome and so on)or patients with dialysis 4. Patients with the history of serious hepatic diseases. 5. Patients with history of myocardial infarction, congestive heart failure, unstable angina, cerebrovascular disease within 6 months prior to screening visit (confirmation of eligibility) 6. Patients with history of or concurrent complication that affect digestive function 7. Patients with the history of serious diabetic complications requiring treatment 8. Patients with history of malignant tumor 9. Patients with a history of drug allergies that interfere with participation in the clinical trial. 10. Patients suspected of alcohol or drug abuse. 11. Pregnant women, nursing mothers, or patients who do not agree to contraception during study period. 12. Patients with diabetes receiving SGLT2 inhibitor in the 8 weeks prior to screening period. 13. Patients who are judged as inappropriate by investigators on screening examination.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c GFR(measure with inulin clearance) | — |
Countries
Japan
Contacts
Public ContactKatsushige Abe
Abe Diabetes Clinic internal medicine
Outcome results
None listed